Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

v3.8.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY - USD ($)
Total
Common Stock [Member]
Common Stock Issuable [Member]
Additional Paid In Capital [Member]
Stockholder Note Receivable [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Series A [Member]
Series B [Member]
Balance at Dec. 31, 2015 $ 6,086,766 $ 76,573 $ 0 $ 71,209,530 $ (58,824) $ 114,788 $ (65,255,301) $ 0 $ 0
Balance (in shares) at Dec. 31, 2015   7,657,287 0         0 0
Stock-Based Compensation 510,995     510,995      
Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition 2,909,766 $ 6,891 $ 291,536 2,611,339      
Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition (in shares)   689,157 76,571        
Issuance of Holdback Shares from the Jade Acquisition 0 $ 227 $ (86,329) 86,102      
Issuance of Holdback Shares from the Jade Acquisition (in shares)   22,674 (22,674)        
Forfeiture of Holdback Shares from the Jade Acquisition 0   $ (205,207) 205,207      
Forfeiture of Holdback Shares from the Jade Acquisition (in shares)     (53,897)        
Issuance of Common Stock in Offering, Net of Offering Costs 668,437 $ 4,410   664,027      
Issuance of Common Stock in Offering, Net of Offering Costs (in shares)   441,000          
Issuance of Series A Preferred Stock, Net of Offering Costs 2,776,447     2,776,419       $ 28
Issuance of Series A Preferred Stock, Net of Offering Costs (in shares)               2,777
Conversion of Series A Preferred 0 $ 12,340   (12,312)       $ (28)
Conversion of Series A Preferred (in shares)   1,234,000           (2,777)
Exercise of Common Stock Options $ 56,206 $ 868   55,338      
Exercise of Common Stock Options (in shares)   86,765          
Issuance of Common Stock from Employee Stock Purchase Plan (in shares) 0                
Foreign Currency Translation Adjustment $ 5,399         5,399  
Net Loss (13,343,437)           (13,343,437)
Balance at Dec. 31, 2016 (329,421) $ 101,309 $ 0 78,106,645 (58,824) 120,187 (78,598,738) $ 0 $ 0
Balance (in shares) at Dec. 31, 2016   10,130,883 0         0 0
Stock-Based Compensation 870,308     870,308      
Cancellation of Stockholder Note Receivable 58,824       58,824    
Issuance of Common Stock in Offering, Net of Offering Costs 8,611,683 $ 59,788   8,551,895      
Issuance of Common Stock in Offering, Net of Offering Costs (in shares)   5,978,817          
Issuance of Series B Preferred Stock, Net of Offering Costs 1,977,500     1,977,480       $ 20
Issuance of Series B Preferred Stock, Net of Offering Costs (in shares)               1,995
Conversion of Series B Preferred Stock 0 $ 9,300   (9,286)       $ (14)
Conversion of Series B Preferred Stock (in shares)   930,000           (1,395)
Exercise of Common Stock Options 40,718 $ 611   40,107      
Exercise of Common Stock Options (in shares)   61,078          
Issuance of Restricted Stock, Net of Cancellations 0 $ 1,030   (1,030)      
Issuance of Restricted Stock, Net of Cancellations (in shares)   103,000          
Issuance of Common Stock from Employee Stock Purchase Plan $ 54,097 $ 535   53,562      
Issuance of Common Stock from Employee Stock Purchase Plan (in shares) 158,000 53,477          
Foreign Currency Translation Adjustment $ 7,286         7,286  
Net Loss (13,217,917)           (13,217,917)
Balance at Dec. 31, 2017 $ (1,926,922) $ 172,573   $ 89,589,681 $ 0 $ 127,473 $ (91,816,655) $ 0 $ 6
Balance (in shares) at Dec. 31, 2017   17,257,255           0 600